Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.

Advertisement

Related Content

FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
FDA Cites Adulteration In Warning Letter To Juice Beauty Manufacturer
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry

Topics

Advertisement
UsernamePublicRestriction

Register

PS079455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel